中华网3 天
赛诺菲欲出售Opella，GSK、辉瑞、强生……MNC剥离消费者健康业务成风？
根据最新报道，赛诺菲正在与CD&R进行深入谈判，计划出售Opella ...
有望成为20年来首款！GSK潜在"first-in-class"小分子疗法获FDA优先审评资格
▎药明康德内容团队编辑GSK今天宣布，美国FDA已接受其潜在"first-in-class"口服抗生素gepotidacin的新药申请（NDA），用于治疗患有单纯性尿路感染（uUTI，也称为急性膀胱炎）成年或青少年（≥12岁）女性患者，患者体重须≥4 ...
中华网8 天
辉瑞终止口服RSV疗法开发！聚焦RSV疫苗，与GSK杠上了？
近日，辉瑞宣布终止针对呼吸道合胞病毒（RSV）治疗药物sisunatovir的开发。根据10月7日ClinicalTrials.gov网站的更新，辉瑞已经停止了两项关于sisunatovir治疗RSV感染的临床研究。
GlobalData on MSN1 天
mRNA licensing agreements surge 800% amid GSK lawsuits
It follows a similar lawsuit against Pfizer and BioNTech filed in April in which GSK alleges the companies were in violation ...
葛兰素史克(GSK.US)同意支付22亿美元以解决约8万起胃灼热药物Zantac ...
智通财经获悉，葛兰素史克(GSK.US)周三宣布，该公司已同意支付高达22亿美元，以解决美国州法院提起的大多数诉讼，这些诉讼指控一种已停产的胃灼热药物Zantac会导致癌症。该公司说，与10家原告律师事务所达成的协议解决了约8万起案件，占美国全国州法 ...
Axios on MSN3 天
GSK sues Moderna over mRNA vaccine technology
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
pharmaphorum4 天
GSK turns its guns on Moderna in mRNA jab patent dispute
The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...
GSK Says Potential Blockbuster Helps Treat Common Nasal Disease
GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...
GSK公布depemokimab三期临床试验结果喜人
GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...
GSK就mRNA专利权起诉Moderna
英国制药公司葛兰素史克（GlaxoSmithKline）在特拉华州的一家联邦法院对美国Moderna公司提起诉讼。GSK声称Moderna在开发和销售其COVID-19疫苗Spikevax的过程中侵犯了GSK与信使RNA（mRNA）技术相关的专利。 该诉讼声称，Moderna用于将mRNA传递到细胞中的脂质纳米粒子侵犯了GSK的专利。根据GSK的说法，这些专利是Moderna疫苗产品所使用的mRN ...